# Klebsiella pneumoniae vaccines: Evolving the blueprint from traditional platforms to mucosal and nanoscale delivery

## TL;DR

This review explores new vaccine strategies against Klebsiella pneumoniae, focusing on nanoscale and mucosal delivery to combat antibiotic-resistant strains.

## Contribution

The paper introduces nanovaccines and mucosal delivery as novel approaches for Klebsiella pneumoniae immunization.

## Key findings

- Nanovaccines like outer membrane vesicles and glycoconjugate nanoparticles show promise for KP immunization.
- Mucosal vaccination strategies may block infection at the site of colonization.
- Traditional and modern vaccine platforms are compared to guide future KP vaccine development.

## Abstract

Klebsiella pneumoniae (KP) is a critical global health threat due to carbapenem-resistant and hypervirulent strains, necessitating effective vaccines amid declining antibiotic efficacy. This review provides a timely and systematic analysis of the current KP vaccine landscape. We first outline the epidemiology of classical and hypervirulent KP (hvKP) and the corresponding protective host immunity, establishing a foundation for vaccination. A detailed survey of key antigenic targets, including polysaccharides and proteins, is presented. The core of this review critically assesses the spectrum of vaccine platforms, from traditional whole-cell and subunit vaccines to nanovaccine platforms. Distinctively, we place a dedicated focus on two transformative frontiers: nanovaccines—such as outer membrane vesicles (OMVs) and biosynthetic glycoconjugate nanoparticles—and mucosal vaccination strategies, emphasizing their unparalleled potential to block infection at the primary site of colonization. By synthesizing cutting-edge preclinical advances and addressing persistent translational challenges, this review serves as a timely and comprehensive resource, offering valuable insights to guide the future development of effective immunization strategies against this formidable pathogen.

Image 1